1421503-40-3

Basic information

• Product Name: (2-{[2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5-ethyl-phenoxy]methoxy}ethyl)(trimethyl)silane
• Synonyms: (2-{[2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5-ethyl-phenoxy]methoxy}ethyl)(trimethyl)silane
• CAS NO: 1421503-40-3
• Molecular Weight: 396.382
• Mol File: 1421503-40-3.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: (2-{[2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5-ethyl-phenoxy]methoxy}ethyl)(trimethyl)silane(CAS DataBase Reference)
• NIST Chemistry Reference: (2-{[2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5-ethyl-phenoxy]methoxy}ethyl)(trimethyl)silane(1421503-40-3)
• EPA Substance Registry System: (2-{[2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5-ethyl-phenoxy]methoxy}ethyl)(trimethyl)silane(1421503-40-3)

Safety Data

• Hazardous Substances Data: 1421503-40-3(Hazardous Substances Data)

Usage

Description

(2-[2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5-ethyl-phenoxy]methoxyethyl)(trimethyl)silane is a complex organosilane molecule that consists of a silane group attached to a larger organic moiety containing fluorine, boron, and ethyl groups. The presence of the boron-containing group suggests that this compound is likely used in organic synthesis as a reagent or catalyst. The trimethylsilyl group at the end of the molecule contributes to the compound's reactivity and solubility in organic solvents, making it a versatile building block for the preparation of new materials or as a reagent for the modification of existing organic molecules in scientific research and industrial processes.

Uses

Used in Organic Synthesis:
(2-[2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5-ethyl-phenoxy]methoxyethyl)(trimethyl)silane is used as a reagent or catalyst in organic synthesis for its ability to facilitate various chemical reactions and transformations.
Used in Material Science:
In the Material Science industry, (2-[2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5-ethyl-phenoxy]methoxyethyl)(trimethyl)silane is used as a building block for the preparation of new materials, taking advantage of its unique structure and reactivity.
Used in Research Applications:
(2-[2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5-ethyl-phenoxy]methoxyethyl)(trimethyl)silane is used as a research reagent for the modification of existing organic molecules, enabling scientists to explore new chemical properties and potential applications.

Upstream product

• 459-47-2 1-ethyl-4-fluorobenzene 
• 112204-58-7 5-Bromo-2-fluorophenol 
• 1421503-39-0 (2-((4-bromo-5-ethyl-2-fluorophenoxy)methoxy)ethyl)-trimethylsilane 
• 73183-34-3 bis(pinacol)diborane 
• 891843-05-3 5-ethyl-2-fluoro-phenol 
• 1421503-38-9 4-bromo-5-ethyl-2-fluoro-phenol 

Downstream Products

• 1421503-41-4 6-[2-ethyl-5-fluoro-4-(2-trimethylsilanyl-ethoxymethoxy)phenyl]-1-(tetrahydro-pyran-2-yl)-1H-indazole-3-carbonitrile 
• 1421503-42-5 6-[2-ethyl-5-fluoro-4-(2-trimethylsilanyl-ethoxymethoxy)phenyl]-1-(tetrahydro-pyran-2-yl)-1H-indazole-3-carboximidic acid methyl ester 
• 1421503-43-6 N-(1-benzyl-4,4-diethoxy-piperidin-3-yl)-6-[2-ethyl-5-fluoro-4-(2-trimethylsilanyl-ethoxymethoxy)phenyl]-1-(tetrahydro-pyran-2-yl)-1H-indazole-3-carboxamidine 
• 1421503-44-7 4,4-diethoxy-3-{[6-[2-ethyl-5-fluoro-4-(2-trimethylsilanyl-ethoxymethoxy)phenyl]-1-(tetrahydro-pyran-2-yl)-1H-indazole-3-carboximidoyl]amino}piperidine-1-carboxylic acid tert-butyl ester 
• 1421502-61-5 N-(1-benzyl-4,4-diethoxy-piperidin-3-yl)-6-(2-ethyl-5-fluoro-4-hydroxy-phenyl)-1-(tetrahydro-pyran-2-yl)-1H-indazole-3-carboxamidine 

Relevant articles and documents

Investigation of Janus Kinase (JAK) Inhibitors for Lung Delivery and the Importance of Aldehyde Oxidase Metabolism

The Janus family of tyrosine kinases (JAK1, JAK2, JAK3, and TYK2) play an essential role in the receptor signaling of cytokines that have been implicated in the pathogenesis of severe asthma, and there is emerging interest in the development of small-molecule-inhaled JAK inhibitors as treatments. Here, we describe the optimization of a quinazoline series of JAK inhibitors and the results of mouse lung pharmacokinetic (PK) studies where only low concentrations of parent compound were observed. Subsequent investigations revealed that the low exposure was due to metabolism by aldehyde oxidase (AO), so we sought to identify quinazolines that were not metabolized by AO. We found that specific substituents at the quinazoline 2-position prevented AO metabolism and this was rationalized through computational docking studies in the AO binding site, but they compromised kinome selectivity. Results presented here highlight that AO metabolism is a potential issue in the lung.

Design and synthesis of a Pan-Janus kinase inhibitor clinical candidate (PF-06263276) suitable for inhaled and topical delivery for the treatment of inflammatory diseases of the lungs and skin

By use of a structure-based computational method for identification of structurally novel Janus kinase (JAK) inhibitors predicted to bind beyond the ATP binding site, a potent series of indazoles was identified as selective pan-JAK inhibitors with a type 1.5 binding mode. Optimization of the series for potency and increased duration of action commensurate with inhaled or topical delivery resulted in potent pan-JAK inhibitor 2 (PF-06263276), which was advanced into clinical studies.